Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03097328 · ClinicalTrials.gov registry record · Phase 2
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Bradley A. McGregor, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT03097328 is a Phase 2 study that has completed, run by Bradley A. McGregor, MD. The registered enrollment target is 39 participants.
The verdict
NCT03097328, a Phase 2 study, has completed, sponsored by Bradley A. McGregor, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.
Interventions
- DRUG TAK-228
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03097328
The ClinicalTrials.gov registry entry for NCT03097328 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bradley A. McGregor, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-228 is the first listed.
NCT03097328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03097328 about?
NCT03097328 is a clinical study titled "Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma". This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.
What is the current status of trial NCT03097328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2017-08-01. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT03097328?
The interventions under investigation include: TAK-228 (DRUG).
Who is sponsoring clinical trial NCT03097328?
This trial is sponsored by Bradley A. McGregor, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.